We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M
This Fund
S&P 500
This Quarter Est. Return
+2.42%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$141M
AUM Growth
+$26.9M
Cap. Flow
+$26.9M
Cap. Flow %
19.02%
Top 10 Hldgs %
81.88%
Holding
105
New
20
Increased
10
Reduced
43
Closed
26

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$35.6M
2
SERA icon
Sera Prognostics
SERA
+$6.17M
3
IRON icon
Disc Medicine
IRON
+$555K
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$535K
5
ARDX icon
Ardelyx
ARDX
+$529K

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$584K
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$554K
3
CGON icon
CG Oncology
CGON
+$552K
4
BLTE
Belite Bio
BLTE
+$551K
5
APLS
Apellis Pharmaceuticals
APLS
+$549K

Sector Composition

Rank Sector Weight
1 Healthcare 24.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
76
Amylyx Pharmaceuticals
AMLX
$4.1B
$151K 0.11%
10,838
-33,385
-75% -$470K
OLMA icon
77
Olema Pharmaceuticals
OLMA
$951M
$149K 0.11%
10,000
-9,063
-48% -$202K
EYPT icon
78
EyePoint Inc
EYPT
$434M
$129K 0.09%
10,000
-19,530
-66% -$292K
OCUL icon
79
Ocular Therapeutix
OCUL
$2.38B
$127K 0.09%
15,000
-27,853
-65% -$265K
ACLX
80
DELISTED
Arcellx
ACLX
– –
-8,224
Closed -$536K
APLS
81
DELISTED
Apellis Pharmaceuticals
APLS
– –
-21,866
Closed -$549K
ARWR icon
82
Arrowhead Research
ARWR
$12.6B
– –
-6,689
Closed -$444K
BEAM icon
83
Beam Therapeutics
BEAM
$3.09B
– –
-18,334
Closed -$508K
BLTE
84
Belite Bio
BLTE
$6.37B
– –
-3,443
Closed -$551K
BMRN icon
85
BioMarin Pharmaceuticals
BMRN
$12.8B
– –
-8,772
Closed -$521K
CGON icon
86
CG Oncology
CGON
$6.95B
– –
-13,293
Closed -$552K
CNTA
87
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-21,879
Closed -$547K
DNLI icon
88
Denali Therapeutics
DNLI
$3.92B
– –
-31,762
Closed -$524K
GPCR icon
89
Structure Therapeutics
GPCR
$3.51B
– –
-6,719
Closed -$467K
INSM icon
90
Insmed
INSM
$27.2B
– –
-3,049
Closed -$531K
JAZZ icon
91
Jazz Pharmaceuticals
JAZZ
$16.4B
– –
-3,258
Closed -$554K
LQDA icon
92
Liquidia Corp
LQDA
$6.39B
– –
-15,485
Closed -$534K
MLYS icon
93
Mineralys Therapeutics
MLYS
$2.29B
– –
-14,818
Closed -$538K
NUVL
94
DELISTED
Nuvalent
NUVL
– –
-5,261
Closed -$529K
ROIV icon
95
Roivant Sciences
ROIV
$26.6B
– –
-24,621
Closed -$534K
RVMD icon
96
Revolution Medicines
RVMD
$45B
– –
-6,872
Closed -$547K
RYTM icon
97
Rhythm Pharmaceuticals
RYTM
$7.67B
– –
-4,738
Closed -$507K
TERN
98
DELISTED
Terns Pharmaceuticals
TERN
– –
-13,560
Closed -$548K
TVTX icon
99
Travere Therapeutics
TVTX
$6.31B
– –
-15,272
Closed -$584K
VRDN icon
100
Viridian Therapeutics
VRDN
$2.76B
– –
-16,967
Closed -$528K
1 2 3
4
5

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
AIMA
Ables Iannone Moore & Associates Savannah, Georgia $188M AUM 26.75% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return

PSP Research's Q1 2026 Portfolio in Review

As of Q1 2026, PSP Research held 105 positions worth $141M, up 24% from $114M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

PSP Research deployed $26.9M of net new capital in Q1 2026, opening 20 new positions and adding to 10 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 284,900 shares worth $36.4M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 39% a quarter earlier.

On the sell side, the largest reduction was Amylyx Pharmaceuticals, an estimated $470K trimmed.

  • PSP Research's largest Q1 2026 buy was State Street SPDR S&P Biotech ETF: 284,900 shares worth $36.4M.
  • PSP Research added most to Alnylam Pharmaceuticals in Q1 2026, an estimated $50K increase.
  • PSP Research's biggest Q1 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $470K.
  • PSP Research fully exited Travere Therapeutics in Q1 2026, selling an estimated $584K.
  • PSP Research's ten largest holdings make up 82% of its $141M portfolio in Q1 2026.
  • PSP Research opened 20 new positions and closed 26 in Q1 2026.
  • PSP Research's portfolio value rose 24% quarter-over-quarter to $141M.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.